Onco Actu du 9 novembre 2016

	1. Biologie
Scientists discover cells that may fuel brain tumour growth [Cancer Research UK] "Our work strongly supports that cancer stem cells are the main source of growth in these tumours and, as such, should be considered promising targets for treatment."
	2. Etiologie
Common food additives 'linked' to bowel cancer [NHS Choices] It's too early to apply these findings to humans. While it's well known that bowel cancer is linked to high levels of body fat and higher consumption of processed meats, the link with emulsifiers is one that needs to be researched further.
	3.1 Tabac
California approves tax increase on cigarettes [Reuters] California's Proposition 56 will increase taxes on a pack of cigarette from 87 cents to $2.87, bringing it more in line with other states. The measure also sets a tax on electronic cigarettes.
	3.1.1 Tabac - e-cigs
Could changes to a global tobacco treaty harm health? [STAT] We hope the FCTC delegates have a successful and productive meeting. But we urge them to carefully consider all the options, because lives are at stake. Making unwise and premature decisions about e-cigarettes could add to the burden of ill health instead of reducing it.
	4.1 Dép., diag. & prono. - Prostate
Second opinions not likely to change prostate cancer treatment [Reuters] The researchers surveyed about 2,000 men who were newly diagnosed with localized prostate cancer in the Philadelphia area between 2012 and 2014. Forty percent sought a second opinion after diagnosis, often to get more information about the cancer. Only 20 percent of men who sought another opinion said they were not satisfied with their first doctor.
	4.9 Dép., diag. & prono. - Sein
Detecting breast cancer from tears? Facebook video news story is just long enough to mislead [HealthNewsReview] The video seems to suggest the value might be in detecting cancer in areas where traditional screening techniques are not available, but of course no one is addressing the issue of overdiagnosis.
	5. Traitements
Researchers find key to drug resistant bowel cancer [Cancer Research UK] Cetuximab is used to treat advanced bowel cancer, and just under half of bowel cancer patients are given the drug. While it helps many patients, there are some for whom it doesn’t work at all and for others it loses effectiveness.
Marker for aggressive prostate cancer doubles-up as a drug target [Cancer Research UK] “Using antibodies mounted with a toxic payload, we can exploit the fact that aggressive prostate cancer cells have more NAALADL2. The next step is to further develop this for use in patients, which we hope can be done in a relatively short timeframe.”
	5.10 Traitements - Essais
Tailored, Dense-Dose Chemotherapy for Early Breast Cancer Does Not Result in Significant Improvement in Recurrence-Free Survival [Karolinska Institutet] Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival, and nonhematologic toxic effects were more frequent in the tailored dose-dense group, according to a study appearing in the November 8 issue of JAMA.
	5.12 Immunothérapies
Immunotherapy Strategy for Advanced Skin Cancer Identified [GEN] "This is the first analysis to draw comparison between targeted and immune therapies for BRAF-mutated melanomas," explained senior study investigator Feng Xie.
	5.12.2 Immunothérapies - CAR-T
How to facilitate development of cancer treatment based on genetically modified T-cells [EMA] The workshop, which is organised by the Agency’s Committee for Advanced Therapies (CAT), aims to facilitate dialogue between the CAT and medicine developers from industry and academia on current scientific developments, regulatory requirements for product manufacture and clinical development of these medicines.
	5.2 Pharma
BioInvent hit with clinical hold on midstage myeloma test [FierceBiotech] In a brief update, the biotech said the full clinical hold was prompted by an “adverse cardiopulmonary event” in the study--although no further details were given as its exec team awaits a written confirmation of the halt.
Mylan seeks FDA approval for biosimilar Herceptin copy [FierceBiotech] Getting a submission to FDA puts Mylan and Biocon at the front of a clutch of companies seeking to cannibalize the $6.6 billion Herceptin made for Roche last year. As in Europe, the partners think they are the first to submit for approval of a biosimilar copy of Herceptin.
Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma [Takeda] Data from ECHELON-2 Phase 3 Trial Expected in 2017 to 2018 Timeframe.
	5.3 Traitements - FDA, EMA, NICE...
FDA to hold two-day meeting on off-label drug marketing [STAT] After years of anticipation, the Food and Drug Administration will hold a public, two-day meeting starting on Wednesday to review the extent to which so-called off-label information about medicines may be disseminated to physicians.
How Big Data Can Be Used for the Development and Regulation of Medicines [ESMO] EMA workshop broadcast live on 14-15 November 2016.
	5.6 ESMO
All for one, and one for all! Patient power at ESMO 16 [The Cancer Blog] This was not just for the medics, what we as a group had to say was just as important and relevant as anything that was revealed at the scientific presentation sessions. The topics covered were wide ranging and engaging, they ran not in parallel with the scientific sessions, but were given proper respect within the running order and it showed.
	6. Lutte contre les cancers
NCRI Cancer Conference 2016: Day 3 – prostate cancer, iKnife surgery, evolving tumours and more [Cancer Research UK] Another day, and another round of headlines this morning from the NCRI Cancer Conference. 1 in 6 women diagnosed with breast cancer have a symptom other than a lump, according to conference research picked up by the BBC and Mail Online. And it turns out gold might be precious in more than one way, as scientists use tiny gold nanoparticles to get a cancer drug inside the heart of tumour cells. The Express has more on this one.
NCRI Cancer Conference 2016: Day 2 – blood tests, virus treatments, preventing cancer and more [Cancer Research UK] A cold Monday morning in Liverpool brought with it a raft of fresh headlines from the conference.
	6.1 Observation
Childhood cancer survivors live longer, but not necessarily with better health [Cancer Research UK] The study took data from the Childhood Cancer Survivor Study, which includes information on health status provided by patients from more than 14,000 adult childhood cancer survivors treated between 1970 and 1999.
	6.10.1 Politiques (USA)
Prop. 61: Californians appear to say no to lowering drug costs [STAT] California voters on Tuesday looked to be defeating a drug pricing control ballot proposition, a major victory for the pharmaceutical industry in its efforts to blunt attempts to drive down high drug prices if the trend holds as the rest of the votes are counted.